Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ba-34,276
2. Ba34,276
3. Deprilept
4. Dibencycladine
5. Hydrochloride, Maprotiline
6. Ludiomil
7. Maprolu
8. Maprotilin
9. Maprotilin Holsten
10. Maprotilin Neuraxpharm
11. Maprotilin Ratiopharm
12. Maprotilin Teva
13. Maprotilin Von Ct
14. Maprotilin-neuraxpharm
15. Maprotilin-ratiopharm
16. Maprotilin-teva
17. Maprotiline
18. Maprotiline Mesylate
19. Mesylate, Maprotiline
20. Mirpan
21. N-methyl-9,10-ethanoanthracene-9(10h)-propylamine
22. Novo Maprotiline
23. Novo-maprotiline
24. Psymion
1. 10347-81-6
2. Maprotiline Hcl
3. Ludiomil
4. Psymion
5. Deprilept
6. 9-(gamma-methylaminopropyl)-9,10-dihydro-9,10-ethanoanthracene Hydrochloride
7. Maprotilline Hcl
8. Maprotiline (hydrochloride)
9. Maprotiline, Hcl
10. Maprotiline Hydrochlorine
11. Nsc-757085
12. 9,10-ethanoanthracene-9(10h)-propanamine, N-methyl-, Hydrochloride
13. 7c8j54pvfi
14. Mls000069552
15. Mls000557000
16. N-methyl-9,10-ethanoanthracene-9(10h)-propanamine Hydrochloride
17. N-methyl-9,10-ethanoanthracene-9(10h)-propylamine Hydrochloride
18. 3-(9,10-ethanoanthracen-9(10h)-yl)-n-methylpropan-1-amine Hydrochloride
19. Ba-34,276
20. Smr000058834
21. Smr000148117
22. 1-(3-methylaminopropyl)dibenzo(b,e)bicyclo(2.2.2)octadiene Hydrochloride
23. Ba-34276
24. Ciba 34276 Ba
25. 1-(3-methylaminopropyl)dibenzo[b,e]bicyclo[2.2.2]octadienehydrochloride;1-(3-methylaminopropyl)dibenzo[b,e]bicyclo[2.2.2]octadienehydrochloride
26. Sr-01000076016
27. Einecs 233-758-8
28. Cas-10347-81-6
29. Unii-7c8j54pvfi
30. Ba 34276
31. Maprotilinehcl
32. Maprotiline Hydrochloride [jan]
33. 1-(3-methylaminopropyl)dibenzo[b,e]bicyclo[2.2.2]octadiene Hydrochloride
34. Ludiomil (tn)
35. Prestwick_749
36. Maprotiline Hydrochloride [usp:jan]
37. Mfcd00079464
38. Cpd000148117
39. Opera_id_513
40. Opera_id_1466
41. Dsstox_cid_24507
42. Dsstox_rid_80277
43. Dsstox_gsid_44507
44. Mls000758284
45. Mls001148189
46. Mls001423998
47. Schembl121014
48. Spectrum1500373
49. Regid_for_cid_71478
50. Chebi:6691
51. Chembl1200427
52. Chembl1237135
53. Dtxsid2044507
54. Maprotiline Hcl;ludiomil;psymion
55. Ba-34276 Hydrochloride
56. Hms1569e13
57. Hms1920j13
58. Kuc112481c
59. Pharmakon1600-01500373
60. Maprotiline, Ludiomil Hydrochloride
61. Bcp23366
62. Hy-b0444
63. Str09724
64. Tox21_300992
65. Tox21_500812
66. 9,10-ethanoanthracene-9(10h)-propylamine, N-methyl-, Hydrochloride
67. Ccg-38957
68. Nsc757085
69. S2517
70. Maprotiline Hydrochloride [mi]
71. Akos015961872
72. Akos015994755
73. Maprotiline Hydrochloride (jp17/usp)
74. Ac-8249
75. Bcp9000894
76. Ccg-220346
77. Ks-5095
78. Lp00812
79. Nc00056
80. Nsc 757085
81. Maprotiline Hydrochloride [mart.]
82. Maprotiline Hydrochloride [vandf]
83. Ncgc00094145-01
84. Ncgc00094145-02
85. Ncgc00094145-03
86. Ncgc00094145-04
87. Ncgc00254894-01
88. Ncgc00261497-01
89. Bm164655
90. Ksc-315-031-
91. Maprotiline Hydrochloride [usp-rs]
92. Maprotiline Hydrochloride [who-dd]
93. Bcp0726000234
94. Eu-0100812
95. Ft-0659758
96. M2527
97. Sw196892-3
98. D00818
99. M 9651
100. Maprotiline Hydrochloride [ep Monograph]
101. Maprotiline Hydrochloride [orange Book]
102. T71539
103. Maprotiline Hydrochloride [usp Monograph]
104. Maprotiline Hydrochloride, >99% (hplc), Powder
105. 347m816
106. A907819
107. Sr-01000000134
108. J-000980
109. Sr-01000000134-3
110. Sr-01000076016-1
111. Sr-01000076016-3
112. Q27268058
113. Maprotiline Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
114. 3-(9,10-ethanoanthracen-9(10h)-yl)-n-methylpropan-1-aminehydrochloride
115. Maprotiline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
116. Maprotiline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
117. Hydron;n-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine;chloride
118. Maprotiline Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
119. Methyl(3-{tetracyclo[6.6.2.0(2),?.0?,(1)?]hexadeca-2,4,6,9,11,13-hexaen-1-yl}propyl)amine Hydrochloride
120. Methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl}propyl)amine Hydrochloride
121. N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine;hydrochloride
Molecular Weight | 313.9 g/mol |
---|---|
Molecular Formula | C20H24ClN |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 4 |
Exact Mass | 313.1597275 g/mol |
Monoisotopic Mass | 313.1597275 g/mol |
Topological Polar Surface Area | 12 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 339 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Maprotiline hydrochloride |
Drug Label | Maprotiline hydrochloride, USP is a tetracyclic antidepressant, available as 25 mg, 50 mg and 75 mg tablets for oral administration. Its chemical name is N-methyl-9,10-ethanoanthracene-9(10H)-propylamine hydrochloride, and its structural formula is:C... |
Active Ingredient | Maprotiline hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 75mg; 50mg |
Market Status | Prescription |
Company | Mylan |
2 of 2 | |
---|---|
Drug Name | Maprotiline hydrochloride |
Drug Label | Maprotiline hydrochloride, USP is a tetracyclic antidepressant, available as 25 mg, 50 mg and 75 mg tablets for oral administration. Its chemical name is N-methyl-9,10-ethanoanthracene-9(10H)-propylamine hydrochloride, and its structural formula is:C... |
Active Ingredient | Maprotiline hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 75mg; 50mg |
Market Status | Prescription |
Company | Mylan |
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
49
PharmaCompass offers a list of MAPROTILINE HYDROCHLORIDE API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right MAPROTILINE HYDROCHLORIDE manufacturer or MAPROTILINE HYDROCHLORIDE supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred MAPROTILINE HYDROCHLORIDE manufacturer or MAPROTILINE HYDROCHLORIDE supplier.
PharmaCompass also assists you with knowing the MAPROTILINE HYDROCHLORIDE API Price utilized in the formulation of products. MAPROTILINE HYDROCHLORIDE API Price is not always fixed or binding as the MAPROTILINE HYDROCHLORIDE Price is obtained through a variety of data sources. The MAPROTILINE HYDROCHLORIDE Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A MAPROTILINE HYDROCHLORIDE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of MAPROTILINE HYDROCHLORIDE, including repackagers and relabelers. The FDA regulates MAPROTILINE HYDROCHLORIDE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. MAPROTILINE HYDROCHLORIDE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of MAPROTILINE HYDROCHLORIDE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A MAPROTILINE HYDROCHLORIDE supplier is an individual or a company that provides MAPROTILINE HYDROCHLORIDE active pharmaceutical ingredient (API) or MAPROTILINE HYDROCHLORIDE finished formulations upon request. The MAPROTILINE HYDROCHLORIDE suppliers may include MAPROTILINE HYDROCHLORIDE API manufacturers, exporters, distributors and traders.
click here to find a list of MAPROTILINE HYDROCHLORIDE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A MAPROTILINE HYDROCHLORIDE DMF (Drug Master File) is a document detailing the whole manufacturing process of MAPROTILINE HYDROCHLORIDE active pharmaceutical ingredient (API) in detail. Different forms of MAPROTILINE HYDROCHLORIDE DMFs exist exist since differing nations have different regulations, such as MAPROTILINE HYDROCHLORIDE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A MAPROTILINE HYDROCHLORIDE DMF submitted to regulatory agencies in the US is known as a USDMF. MAPROTILINE HYDROCHLORIDE USDMF includes data on MAPROTILINE HYDROCHLORIDE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The MAPROTILINE HYDROCHLORIDE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of MAPROTILINE HYDROCHLORIDE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The MAPROTILINE HYDROCHLORIDE Drug Master File in Japan (MAPROTILINE HYDROCHLORIDE JDMF) empowers MAPROTILINE HYDROCHLORIDE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the MAPROTILINE HYDROCHLORIDE JDMF during the approval evaluation for pharmaceutical products. At the time of MAPROTILINE HYDROCHLORIDE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of MAPROTILINE HYDROCHLORIDE suppliers with JDMF on PharmaCompass.
A MAPROTILINE HYDROCHLORIDE CEP of the European Pharmacopoeia monograph is often referred to as a MAPROTILINE HYDROCHLORIDE Certificate of Suitability (COS). The purpose of a MAPROTILINE HYDROCHLORIDE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of MAPROTILINE HYDROCHLORIDE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of MAPROTILINE HYDROCHLORIDE to their clients by showing that a MAPROTILINE HYDROCHLORIDE CEP has been issued for it. The manufacturer submits a MAPROTILINE HYDROCHLORIDE CEP (COS) as part of the market authorization procedure, and it takes on the role of a MAPROTILINE HYDROCHLORIDE CEP holder for the record. Additionally, the data presented in the MAPROTILINE HYDROCHLORIDE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the MAPROTILINE HYDROCHLORIDE DMF.
A MAPROTILINE HYDROCHLORIDE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. MAPROTILINE HYDROCHLORIDE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of MAPROTILINE HYDROCHLORIDE suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing MAPROTILINE HYDROCHLORIDE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for MAPROTILINE HYDROCHLORIDE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture MAPROTILINE HYDROCHLORIDE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain MAPROTILINE HYDROCHLORIDE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a MAPROTILINE HYDROCHLORIDE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of MAPROTILINE HYDROCHLORIDE suppliers with NDC on PharmaCompass.
MAPROTILINE HYDROCHLORIDE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of MAPROTILINE HYDROCHLORIDE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right MAPROTILINE HYDROCHLORIDE GMP manufacturer or MAPROTILINE HYDROCHLORIDE GMP API supplier for your needs.
A MAPROTILINE HYDROCHLORIDE CoA (Certificate of Analysis) is a formal document that attests to MAPROTILINE HYDROCHLORIDE's compliance with MAPROTILINE HYDROCHLORIDE specifications and serves as a tool for batch-level quality control.
MAPROTILINE HYDROCHLORIDE CoA mostly includes findings from lab analyses of a specific batch. For each MAPROTILINE HYDROCHLORIDE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
MAPROTILINE HYDROCHLORIDE may be tested according to a variety of international standards, such as European Pharmacopoeia (MAPROTILINE HYDROCHLORIDE EP), MAPROTILINE HYDROCHLORIDE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (MAPROTILINE HYDROCHLORIDE USP).